← back to search

Esteban Celis

National Cancer Center of Georgia · US
Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, Immune Cell Function and Interaction, vaccines and immunoinformatics approaches, and Cancer Immunotherapy and Biomarkers.
h-index
72
citations
23,978
works
356
NIH funding
primary concept
Biology
email

Recent publications

STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition.
2025cited by 0position: contributordoi
Supplementary Table 2 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
2025cited by 0position: contributordoi
Supplementary Table 1 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
2025cited by 0position: contributordoi
Data from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
2025cited by 0position: contributordoi
Supplemental Figure 3 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
2025cited by 0position: contributordoi
Supplemental Figure 2 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
2025cited by 0position: contributordoi
Supplemental Figure 1 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
2025cited by 0position: contributordoi
Poly-ICLC, a multi-functional immune modulator for treating cancer.
2020cited by 65position: contributordoi
Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration.
2020cited by 48position: contributordoi
Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw.
2020cited by 41position: contributordoi
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.
2020cited by 18position: contributordoi
Double-Stranded RNA Immunomodulators in Prostate Cancer.
2020cited by 2position: contributordoi
Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model.
2019cited by 90position: contributordoi
The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice.
2019cited by 37position: contributordoi
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
2019cited by 15position: contributordoi
Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer
Nature Communications 2017cited by 291position: middledoi
Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
Cancer Immunology Research 2016cited by 76position: lastdoi
The PTEN pathway in T <sub>regs</sub> is a critical driver of the suppressive tumor microenvironment
Science Advances 2015cited by 169position: middledoi
Consensus nomenclature for CD8<sup>+</sup>T cell phenotypes in cancer
OncoImmunology 2015cited by 136position: middledoi
Transnuclear TRP1-Specific CD8 T Cells with High or Low Affinity TCRs Show Equivalent Antitumor Activity
Cancer Immunology Research 2013cited by 62position: middledoi
Vaccine-Elicited CD8 <sup>+</sup> T Cells Protect against Respiratory Syncytial Virus Strain A2-Line19F-Induced Pathogenesis in BALB/c Mice
Journal of Virology 2012cited by 57position: middledoi
A Potent Vaccination Strategy That Circumvents Lymphodepletion for Effective Antitumor Adoptive T-cell Therapy
Cancer Research 2012cited by 38position: lastdoi
Novel Toll-like Receptor 2 Ligands for Targeted Pancreatic Cancer Imaging and Immunotherapy
Journal of Medicinal Chemistry 2012cited by 34position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 10 papers (2019–2025)Hussein Sultan · National Cancer Center of Georgia8 papers (2020–2025)Takumi Kumai · Asahikawa Medical University7 papers (2025–2025)Gregory K. Friedman · The University of Texas MD Anderson Cancer Center7 papers (2025–2025)Joshua D. Bernstock · Koch Institute for Integrative Cancer Research At MIT7 papers (2025–2025)John D. Klement · 7 papers (2025–2025)Aaron E. Fan · The University of Texas MD Anderson Cancer Center7 papers (2025–2025)Juan Wu · Zhejiang Sci-Tech University7 papers (2025–2025)Valentyna I. Fesenkova · 7 papers (2025–2025)Hyun-Il Cho · Catholic University of Korea4 papers (2012–2016)Sujin Lee · Massachusetts General Hospital2 papers (2012–2016) · 1 papers (2015–2015) · 1 papers (2017–2017)Laxminarasimha Donthireddy · The Wistar Institute1 papers (2017–2017)Andrew A. Amoscato · UPMC Hillman Cancer Center1 papers (2017–2017)Vladimir A. Tyurin · University of Pittsburgh1 papers (2017–2017)Dmitry I. Gabrilovich · AstraZeneca (Netherlands)1 papers (2017–2017)Alexandr A. Kapralov · Oklahoma State University Center for Health Sciences1 papers (2017–2017) · 1 papers (2017–2017)Michael Dougan · Harvard University1 papers (2013–2013)